• All
  • Financials
  • Insiders
Webull provides the latest Ventyx Biosciences, Inc. (VTYX) stock and general news. This information may help you make smarter investment decisions.
About VTYX
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of small molecule product candidates to address a range of inflammatory diseases with unmet medical need. Its pipeline includes VTX958, VTX002, VTX2735 and Preclinical NLRP3 Inhibitor Portfolio. The Company’s lead product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor to address a range of immune-mediated diseases, such as psoriasis, inflammatory bowel disease (IBD), psoriatic arthritis and lupus. It is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 (S1P1R) modulator for ulcerative colitis (UC). The Company is also developing a NOD-like receptor protein 3 (NLRP3) inhibitors to address multiple indications driven by NLRP3 inflammasome activation. Its NLRP3 inhibitor and VTX2735 designed to treat systemic inflammatory diseases such as cardiovascular, hepatic, renal, and rheumatologic diseases.